Assessment of initial real life experience with Abiraterone Acetate in patients with castrate resistant prostate cancer: A retrospective study in Saudi Arabian patients
- Department of Medical Oncology, Faculty of Medicine, Zagazig University, Sharkia, Egypt.
- King Faisal Specialist Hospital and College of Medicine, ALFAISAL University, Jeddah, Saudi Arabia.
- Oncology Center, Faculty of Medicine Mansoura University, Mansoura, Egypt.
- Abstract
- Keywords
- Cite This Article as
- Corresponding Author
Background: Abiraterone Acetate (AA) improves outcome of patients and is currently an adopted standard of care in chemo-naïve patients and after progression on chemotherapy. We audited our initial experience with the use of AA in these patients. Patients and methods: Eighteen consecutive CRPC patients were treated with AA 1000 mg/day and prednisolone 5 mg twice daily. Patients achieving prostate specific antigen decline (PSA) ? 50% were considered as marker responders. Results: A total of 10 patients (55.6%) achieved PSA response. The median time to PSA progression was 9 months (95% CI: 4.1-13.8). Objective radiological response was achieved in 6 (33%) patients (2 CR & 4 PR). Three patients (16.7%) achieved SD. After a median follow up of 13 months, the median overall survival was not reached and the mean was 20 (3-23) months. Selected grade III/IV adverse events of special interest were hypokalemia (22%) and hypertension (11%). Conclusion: In daily clinical practice, AA is an effective treatment for patients with CRPC. It produces meaningful marker and objective responses, PFS and OS that are comparable to those reported in clinical trials. Monitoring of blood pressure and serum potassium is recommended.
[Rasha Haggag, Jamal Zekri, Kamel Farag (2015); Assessment of initial real life experience with Abiraterone Acetate in patients with castrate resistant prostate cancer: A retrospective study in Saudi Arabian patients Int. J. of Adv. Res. 3 (Jun). 940-946] (ISSN 2320-5407). www.journalijar.com
